Argenica Therapeutics
Argenica Therapeutics is a clinical stage drug development company focused on developing novel neuroprotective therapeutics to reduce brain damage after stroke and other brain injuries. Their lead candidate, ARG-007, aims to protect brain cells and improve patient recovery, with ongoing clinical trials and a mission to bring effective treatments to market.
Industries
biotechnology
Nr. of Employees
small (1-50)
Products
Clinical‑stage neuroprotective peptide candidate (peptide therapeutic)
A peptide therapeutic developed to protect brain tissue and reduce neuronal cell death following acute brain injury. Supported by preclinical efficacy in multiple rodent models and completed Phase 1 safety/tolerability testing in healthy volunteers; currently under Phase 2 evaluation for acute ischemic stroke.
Clinical‑stage neuroprotective peptide candidate (peptide therapeutic)
A peptide therapeutic developed to protect brain tissue and reduce neuronal cell death following acute brain injury. Supported by preclinical efficacy in multiple rodent models and completed Phase 1 safety/tolerability testing in healthy volunteers; currently under Phase 2 evaluation for acute ischemic stroke.
Expertise Areas
- Neuroprotective drug development
- Preclinical CNS injury modelling (stroke, TBI, HIE)
- Early‑phase clinical trial conduct (Phase 1 and Phase 2)
- Translational neuroscience
Key Technologies
- Peptide therapeutics (poly‑arginine peptides)
- Rodent ischemic stroke models (MCAO and endothelin‑1)
- Rodent traumatic brain injury models
- Perinatal hypoxic‑ischaemic encephalopathy models